Cholesterol Drug Vytorin Fails Key Trial
Results presented at an American College of Cardiology conference in Chicago Sunday, Mar 30th and published on the Internet by the New England Journal of Medicine announced that a key trial of Vytorin failed. Parallel to the report, leading doctors urged the return to the older, successful treatments for high cholesterol, such as statins. Results showed Vytorin failed to improve heart disease even though it worked as intended to reduce three key risk factors. “People need to turn back to statins,” said Yale University cardiologist Dr. Harlan Krumholz, referring to Lipitor, Crestor and other widely used brands. “We know that statins are good drugs. We know that they reduce risks.” Two Congresssional panels ordered investigations into why it took the drug makers almost two years after the study’s completion to release their results.
Continue reading "Cholesterol Drug Vytorin Fails Key Trial " »
